I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

Compared with bare metal stents, drug-eluting stents (DESs) have tremendously increased therapeutic benefits for percutaneous coronary intervention (PCI), predominantly represented by reduced incidence of target vessel revascularization/target lesion revascularization (TVR/TLR).\[[@ref1]\] The first-generation DESs (G1-DESs) adopted sirolimus or paclitaxel as the coated antiproliferative medications, which effectively eliminated coronary arterial neointimal hyperplasia and thus, in-stent restenosis, mitigating the risks of TVR/TLR events.\[[@ref2][@ref3]\] However, safety concerns arose because of late- and very-late stent thrombosis associated with G1-DES,\[[@ref4][@ref5]\] prompting the development of second-generation DESs (G2-DESs). Based on a novel platform design, more biocompatible polymers, and/or lipophilic antiproliferative medications, G2-DESs were demonstrated to have favorable efficacy and safety in patients undergoing PCI.\[[@ref6][@ref7]\] However, G1-DESs are still used in certain countries because of various issues including economics. Controversy remains regarding the performance of G1-DES versus G2-DES.\[[@ref8][@ref9][@ref10]\] Based on our previous report, G1-DES had similar efficacy and safety profiles to those of G2-DES in patients with stable coronary artery disease.\[[@ref11]\] This impelled us to consider whether G2-DESs outperform G1-DESs in patients with acute coronary syndrome (ACS), a disorder with higher risks of adverse events after PCI.\[[@ref12]\] Therefore, we aimed to identify the efficacy and safety of G1-DES and G2-DES in patients with ACS in a high-volume PCI center.

M[ETHODS]{.smallcaps} {#sec1-2}
=====================

Ethical approval {#sec2-1}
----------------

This study met the guidelines of the *Helsinki Declaration* of 1975, as revised in 2000, and was approved by the ethics committee of our institution (No. 2013-449). Each patient provided written informed consent before PCI.

Study population {#sec2-2}
----------------

This was a prospective observational study. In 2013, 10,724 consecutive patients underwent PCI or percutaneous transluminal coronary angioplasty in our hospital. Among these patients, 6431 were diagnosed with ACS, including 4511 patients with unstable angina, 1445 patients with ST-segment elevation myocardial infarction (STEMI), and 475 patients with non-STEMI (NSTEMI). The exclusion criteria were: (1) patients undergoing percutaneous transluminal coronary angioplasty without stent implantation, (2) patients receiving neither G1-DES nor G2-DES, and (3) patients receiving multiple types of stents concurrently. In our center, G1-DES included sirolimus-eluting stents (Cypher, Cordis Corp., Milpitas, CA, USA; Firebird, MicroPort Medical, Shanghai, China; Partner, Lepu Medical Technology Co., Beijing, China) and paclitaxel-eluting stents (Taxus Express2 and Taxus Liberté, Boston Scientific Corporation, Natick, MA, USA), while G2-DES included everolimus-eluting stents (Promus Element, Boston Scientific; Xience V and Xience Prime, Abbott Vascular, Santa Clara, CA, USA), sirolimus-eluting stents (Firebird2, MicroPort Medical), and zotarolimus-eluting stents (Endeavor and Endeavor Resolute, Medtronic, Minneapolis, MN, USA). A final total of 4037 patients were enrolled in this study, including 2865 patients with unstable angina, 875 patients with STEMI, and 297 patients with NSTEMI. Among these, 364 patients underwent G1-DES implantation and 3673 patients underwent G2-DES implantation. In patients receiving staged PCI, data were combined from all phases of the procedure.

Procedure and medications {#sec2-3}
-------------------------

Selective or emergency PCI was performed in all enrolled patients. Before the procedure, patients received aspirin 100 mg/d and clopidogrel 75 mg/d for at least four continuous days. Otherwise, a loading dose of 300 mg aspirin and 300--600 mg clopidogrel were given before PCI. During the procedure, unfractionated heparin (100 U/kg body weight) was administered via the arterial sheath, and an additional 1000 U heparin was given when the procedure lasted for more than 1 h. The use of glycoprotein IIb/IIIa inhibitors was based on the operator\'s judgment, and the decision to implant a G1-DES or G2-DES was based on the agreement between patients and cardiologists, depending on patients\' clinical conditions and economic factors including price and local insurance compensation. After PCI, patients were prescribed aspirin 100 mg/d indefinitely and clopidogrel 75 mg/d for at least 1 year.

Follow-up and endpoints {#sec2-4}
-----------------------

All patients were followed up at 30 days, 6 months, and then annually after PCI. Of the enrolled 4037 patients, 3955 (98.0%) completed the 2-year follow-up. In-hospital data were collected by reviewing patients\' medical records, and follow-up data were collected through medical records, telephone calls, or clinical visits. An independent group of follow-up investigators oversaw data collection, and data accuracy was audited by professional cardiologists. Although not mandatory, patients were advised to return for coronary angiography if an ischemic episode occurred. Efficacy endpoints included major adverse cardiac events (MACEs) and related components, and the safety endpoint was stent thrombosis. MACE was the composite of target vessel-related myocardial infarction (TV-MI), TVR, TLR, and cardiac death. TV-MI was defined as newly occurring MI confirmed by coronary angiography and revealing the target vessel as the culprit lesion, or by electrocardiogram indicating new abnormal ST-T changes and/or left bundle branch block related to the target vessel. TVR was defined as revascularization for a new lesion on the target vessel either by PCI or by coronary artery bypass grafting (CABG), while TLR was defined as revascularization for a new lesion at or within 5 mm of the previously implanted stent either by PCI or by CABG. Cardiac death was defined as death resulting from MI, heart failure, or fatal arrhythmia, and death not attributable to noncardiac reasons. In our study, stent thrombosis included definite, probable, and possible stent thrombosis based on the Academic Research Consortium criteria.\[[@ref13]\]

Statistical analysis {#sec2-5}
--------------------

To minimize the differences in sample size and baseline characteristics between the G1-DES and G2-DES groups, we used propensity score matching (PSM) with the nearest-neighbor algorithm and 1:2 matching to avoid excessive reduction in sample size. The adjusted variables included age, gender, staged PCI, and B~2~/C type lesion. Continuous variables were presented as median (25^th^ and 75^th^ percentile) because they were nonnormally distributed by Kolmogorov-Smirnov testing (all: *P* \< 0.05). These data were compared using the Mann-Whitney *U*-test. Categorical variables were expressed as frequency (percentage) and were compared using Pearson\'s Chi-square or Fisher\'s exact test. We constructed cumulative survival curves for endpoint events using the Kaplan-Meier method and compared them using the log-rank test. We used a Cox proportional regression model to assess the independent predictors of endpoint events. Variables with *P* \< 0.10 in univariate analysis were included in the multivariate Cox regression analysis based on the backward stepwise method. All *P* values were two sided, and *P* \< 0.05 was considered statistically significant. PSM was performed using the MatchIt package in R (R Project for Statistical Computing Version 3.2.4, R Core Team, 2016, <https://www.r-project.org>), and other statistical calculations were performed using SPSS Statistics (Version 22.0, IBM Corp., Armonk, NY, USA).

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

We enrolled 4037 patients diagnosed with ACS and receiving G1-DES or G2-DES implantation, with 364 of the patients receiving G1-DES and 3673 patients receiving G2-DES implants \[[Table 1](#T1){ref-type="table"} and [Table 2](#T2){ref-type="table"}\]. We implanted a total of 6697 coronary stents at 5342 lesion sites. There were obvious differences between the two groups concerning staged PCI, incidence of diabetes mellitus, number of target vessels and lesions, left circumflex artery involvement, number of bifurcation lesions, stent overlapping, stent number and average diameter, and the use of glycoprotein IIb/IIIa inhibitors and low-molecular weight heparin or fondaparinux. Therefore, we used a 1:2 PSM to minimize the imbalances between the two groups and described the adjusted covariates in the statistics section of the methods. All baseline data, and the majority of angiographic and procedural data, were well matched after PSM, except that the number of stents was higher and the average stent diameter was lower in the G2-DES group.

###### 

Baseline patient's characteristics before and after PSM

  Characteristics                Before PSM               Statistics           *P*          
  ------------------------------ ------------------------ -------------------- ------------ ---------
  Age (years)                    59 (51, 64)              58 (50, 66)          0.036\*      0.971
  Male gender                    284 (78.0)               2846 (77.5)          0.055^†^     0.815
  BMI (kg/m^2^)                  25.5 (23.4, 27.7)        25.9 (23.9, 27.8)    1.897\*      0.058
  Hospital stay (days)           5 (4, 7)                 5 (4, 7)             0.375\*      0.707
  Staged PCI                     18 (4.9)                 292 (7.9)            4.218^†^     0.040
  EF (%)                         63.0 (58.9, 67.0)        63.0 (60.0, 67.0)    1.088\*      0.277
  LDL-C (mmol/L)                 2.4 (1.9, 3.0)           2.4 (1.9, 3.0)       −0.461\*     0.645
  eGFR (ml·min^−1^·1.73 m^−2^)   94.0 (82.0, 100.7)       94.4 (83.9, 102.2)   1.021\*      0.307
  Previous MI                    44 (12.1)                440 (12.0)           0.004^†^     0.951
  Previous PCI                   66 (18.1)                786 (21.4)           2.124^†^     0.145
  Previous CABG                  10 (2.7)                 140 (3.8)            1.049^†^     0.306
  Clinical presentation                                                                     
   UA                            249 (68.4)               2616 (71.2)          1.275^†^     0.259
   STEMI                         90 (24.7)                785 (21.4)           2.193^†^     0.139
   NSTEMI                        25 (6.9)                 272 (7.4)            0.140^†^     0.708
  Relevant histories                                                                        
   Hypertension                  236 (64.8)               2295 (62.5)          0.783^†^     0.376
   Hyperlipidemia                228 (62.6)               2429 (66.1)          1.797^†^     0.180
   DM                            86 (23.6)                1067 (29.0)          4.774^†^     0.029
   Smoker                        232 (63.7)               2167 (59.0)          3.084^†^     0.079
   Family history of CAD         80 (22.0)                932 (25.4)           2.050^†^     0.152
   CVD                           33 (9.1)                 364 (9.9)            0.266^†^     0.606
   PVD                           7 (1.9)                  78 (2.1)             0.065^†^     0.799
   COPD                          6 (1.6)                  87 (2.4)             0.763^†^     0.382
                                                                                            
  **Characteristics**            **After PSM**            **Statistics**       ***P***      
                                                                                            
  **G2-DES (*n* = 364)**         **G2-DES (*n* = 728)**                                     
                                                                                            
  Age (years)                    59 (51, 64)              59 (51, 64)          0.002\*      0.999
  Male gender                    284 (78.0)               568 (78.0)           \<0.001^†^   \>0.999
  BMI (kg/m^2^)                  25.5 (23.4, 27.7)        25.7 (23.7, 27.7)    0.812\*      0.417
  Hospital stay (days)           0.417                    5 (4, 7)             0.314\*      0.753
  Staged PCI                     18 (4.9)                 36 (4.9)             \<0.001^†^   \>0.999
  EF (%)                         63.0 (58.9, 67.0)        63.0 (59.6, 67.5)    0.824\*      0.410
  LDL-C (mmol/L)                 2.4 (1.9, 3.0)           2.4 (1.8, 3.0)       −0.961\*     0.336
  eGFR (ml·min^−1^·1.73 m^−2^)   94.0 (82.0, 100.7)       95.6 (85.6, 102.4)   1.704\*      0.088
  Previous MI                    44 (12.1)                96 (13.2)            0.262^†^     0.609
  Previous PCI                   66 (18.1)                157 (21.6)           1.761^†^     0.785
  Previous CABG                  10 (2.7)                 32 (4.4)             1.783^†^     0.182
  Clinical presentation                                                                     
   UA                            249 (68.4)               516 (70.9)           0.707^†^     0.400
   STEMI                         90 (24.7)                155 (21.3)           1.644^†^     0.200
   NSTEMI                        25 (6.9)                 57 (7.8)             0.323^†^     0.570
  Relevant histories                                                                        
   Hypertension                  236 (64.8)               434 (59.6)           2.789^†^     0.095
   Hyperlipidemia                228 (62.6)               485 (66.6)           1.699^†^     0.192
   DM                            86 (23.6)                205 (28.2)           2.551^†^     0.110
   Smoker                        232 (63.7)               424 (58.2)           3.054^†^     0.081
   Family history of CAD         80 (22.0)                179 (24.6)           0.936^†^     0.333
   CVD                           0.333                    70 (9.6)             0.086^†^     0.770
   PVD                           7 (1.9)                  14 (1.9)             \<0.001^†^   \>0.999
   COPD                          6 (1.6)                  17 (2.3)             0.555^†^     0.456

Data were presented as *n* (%) for categorical variables, and median (P~25~, P~75~) for continuous variables. \**Z* value; ^†^*χ*^2^ value. BMI: Body mass index; CABG: Coronary artery bypass grafting; CAD: Coronary artery disease; COPD: Chronic obstructive pulmonary disease; CVD: Cerebrovascular disease; DM: Diabetes mellitus; EF: Ejection fraction; eGFR: Estimated glomerular filtration rate; G1-DES: First-generation drug-eluting stent; G2-DES: Second-generation drug-eluting stent; LDL-C: Low-density lipoprotein-cholesterol; MI: Myocardial infarction; NSTEMI: Non-ST-segment elevation myocardial infarction; PCI: Percutaneous coronary intervention; PVD: Peripheral vascular disease; STEMI: ST-segment elevation myocardial infarction; UA: Unstable angina; PSM: Propensity score matching.

###### 

Patient's angiographic and procedural characteristics before and after PSM

  Characteristics                    Before PSM               Statistics          *P*          
  ---------------------------------- ------------------------ ------------------- ------------ ------------
  Normal origin of CA                348 (99.1)               3515 (99.0)         0.057^†^     0.811
  Right distribution of CA           324 (91.0)               3255 (90.4)         0.122^†^     0.727
  Radial approach PCI                336 (92.3)               3377 (91.9)         0.060^†^     0.806
  Number of TVs                      1 (1, 1)                 1 (1, 1)            2.421\*      0.015
  Number of TLs                      1 (1, 1)                 1 (1, 2)            3.478\*      0.001
   LM involved                       5 (1.4)                  74 (2.0)            0.709^†^     0.400
   LAD involved                      343 (94.2)               3406 (92.7)         1.125^†^     0.289
   LCX involved                      39 (10.7)                534 (14.5)          3.977^†^     0.046
   RCA involved                      38 (10.4)                496 (13.5)          2.709^†^     0.100
   Graft involved                    0 (0.0)                  5 (0.1)             \-           \>0.999^‡^
  *De novo* lesion                   352 (96.7)               3507 (95.5)         1.175^†^     0.278
  B~2~/C type lesion                 252 (69.2)               2709 (73.8)         3.467^†^     0.063
  CTO                                16 (4.4)                 217 (5.9)           1.393^†^     0.238
  Ostial lesion                      51 (14.0)                590 (16.1)          1.044^†^     0.307
  Bifurcation lesion                 49 (13.5)                659 (17.9)          4.597^†^     0.032
  Heavy calcification                57 (15.7)                560 (15.2)          0.044^†^     0.835
  Thrombus extraction                12 (3.3)                 146 (4.0)           0.405^†^     0.524
  Predilation                        348 (95.6)               3480 (94.7)         0.498^†^     0.480
  Postdilation                       247 (67.9)               2489 (67.8)         0.001^†^     0.971
  Stent overlapping                  109 (29.9)               1309 (35.6)         4.711^†^     0.030
  Number of stents                   1 (1, 2)                 1 (1, 2)            3.779\*      \<0.001
  Average stent diameter (mm)        3.2 (2.8, 3.5)           3.0 (2.8, 3.5)      −5.396\*     \<0.001
  Average stent length (mm)          21.0 (18.0, 21.9)        23.0 (18.0, 23.3)   1.683\*      0.092
  IVUS application                   16 (4.4)                 173 (4.7)           0.073^†^     0.786
  IABP application                   5 (1.4)                  44 (1.3)            --           0.800^‡^
  Medication at discharge                                                                      
   Aspirin                           360 (98.9)               3623 (98.6)         0.173^†^     0.678
   Clopidogrel                       356 (97.8)               3614 (98.4)         0.710^†^     0.399
   Glycoprotein IIb/IIIa inhibitor   57 (15.7)                439 (12.0)          4.224^†^     0.040
   LMWH/fondaparinux                 306 (84.1)               3225 (87.8)         4.219^†^     0.040
   Statin                            347 (95.3)               3519 (95.8)         0.186^†^     0.666
   β-blocker                         313 (86.0)               3269 (89.0)         3.004^†^     0.083
   Nitrates                          356 (97.8)               3588 (97.7)         0.020^†^     0.888
   CCB                               179 (49.2)               1833 (49.9)         0.070^†^     0.791
  Duration of DAPT                                                                             
   1 year                            347 (95.3)               3523 (95.9)         0.387^†^     0.592
   2 years                           97 (26.6)                1073 (29.2)         1.058^†^     0.304
                                                                                               
  **Characteristics**                **After PSM**            **Statistics**      ***P***      
                                                                                               
  **G2-DES (*n* = 364)**             **G2-DES (*n* = 728)**                                    
                                                                                               
  Normal origin of CA                348 (99.1)               695 (98.0)          1.866^†^     0.172
  Right distribution of CA           324 (91.0)               654 (91.5)          0.063^†^     0.802
  Radial approach PCI                336 (92.3)               661 (90.8)          0.698^†^     0.404
  Number of TVs                      1 (1, 1)                 1 (1, 1)            0.566\*      0.571
  Number of TLs                      1 (1, 1)                 1 (1, 1)            1.179\*      0.238
   LM involved                       5 (1.4)                  10 (1.4)            \<0.001^†^   \>0.999
   LAD involved                      343 (94.2)               683 (93.8)          0.073^†^     0.788
   LCX involved                      39 (10.7)                87 (12.0)           0.363^†^     0.547
   RCA involved                      38 (10.4)                77 (10.6)           0.005^†^     0.944
   Graft involved                    0 (0.0)                  0 (0.0)             --           --
  *De novo* lesion                   352 (96.7)               690 (94.8)          2.054^†^     0.152
  B~2~/C type lesion                 252 (69.2)               504 (69.2)          \<0.001^†^   \>0.999
  CTO                                16 (4.4)                 33 (4.5)            0.011^†^     0.918
  Ostial lesion                      51 (14.0)                116 (15.9)          0.693^†^     0.405
  Bifurcation lesion                 49 (13.5)                108 (14.8)          0.372†       0.542
  Heavy calcification                57 (15.7)                119 (16.3)          0.085†       0.771
  Thrombus extraction                12 (3.3)                 31 (4.3)            0.593†       0.441
  Predilation                        348 (95.6)               686 (94.2)          0.910†       0.340
  Postdilation                       247 (67.9)               503 (69.1)          0.172†       0.678
  Stent overlapping                  109 (29.9)               241 (33.1)          1.112†       0.292
  Number of stents                   1 (1, 2)                 1 (1, 2)            2.011\*      0.044
  Average stent diameter (mm)        3.2 (2.8, 3.5)           3.0 (2.8, 3.5)      −4.003\*     \<0.001
  Average stent length (mm)          21.0 (18.0, 21.9)        22.0 (18.0, 26.0)   0.490\*      0.624
  IVUS application                   16 (4.4)                 32 (4.4)            \<0.001†     \>0.999
  IABP application                   5 (1.4)                  7 (1.0)             --           0.547‡
  Medication at discharge                                                                      
   Aspirin                           360 (98.9)               717 (98.5)          0.304†       0.581
   Clopidogrel                       356 (97.8)               708 (97.3)          0.293†       0.588
   Glycoprotein IIb/IIIa inhibitor   57 (15.7)                104 (14.3)          0.364†       0.546
   LMWH/fondaparinux                 306 (84.1)               635 (87.2)          2.033†       0.154
   Statin                            347 (95.3)               696 (95.6)          0.043†       0.836
   β-blocker                         313 (86.0)               644 (88.5)          1.369†       0.242
   Nitrates                          356 (97.8)               706 (97.0)          0.617†       0.432
   CCB                               179 (49.2)               369 (50.7)          0.222†       0.638
  Duration of DAPT                                                                             
   1 year                            347 (95.3)               693 (95.2)          0.010†       0.920
   2 years                           97 (26.6)                189 (26.0)          0.059†       0.808

Data were presented as *n* (%) for categorical variables, and median (P~25~, P~75~) for continuous variables. \**Z* value; ^†^*χ*^2^ value; ^‡^Fisher's exact *P* value; \"-\": Not available. CA: Coronary artery; CCB: Calcium channel blocker; CTO: Chronic total occlusion; DAPT: Dual antiplatelet therapy; G1-DES: First-generation drug-eluting stent; G2-DES: Second-generation drug-eluting stent; IABP: Intra-aortic balloon pumping; IVUS: Intravenous ultrasound; LAD: Left anterior descending artery; LCX: Left circumflex artery; LM: Left main artery; LMWH: Low-molecular weight heparin; PCI: Percutaneous coronary intervention; RCA: Right coronary artery; TLs: Target lesions; TVs: Target vessels; PSM: Propensity score matching.

At the 2-year follow-up, the occurrences of MACE and its individual components, as well as stent thrombosis, were similar between the G1-DES and G2-DES groups before PSM (respectively: MACE, 5.2% vs. 4.5%, *χ*^2^ = 0.371, *P* = 0.542; TV-MI, 0.8% vs. 0.7%, *P* = 0.261; TVR, 4.9% vs. 3.6%, *χ*^2^ = 1.537, *P* = 0.215; TLR, *χ*^2^ = 2.697, 3.8% vs. 2.4%, *P* = 0.101; cardiac death, 0.3% vs. 0.8%, *P* = 0.521; and stent thrombosis, 0.5% vs. 1.0%, *P* = 0.575; [Table 3](#T3){ref-type="table"}). The efficacy and safety endpoints were also not significantly different between G1-DES and G2-DES groups after PSM (respectively: MACE, 5.2% vs. 4.3%, *χ*^2^ = 0.514, *P* = 0.474; TV-MI, 0.8% vs. 0.4%, *P* = 0.407; TVR, 4.9% vs. 3.7%, *χ*^2^ = 0.939, *P* = 0.333; TLR, 3.8% vs. 2.5%, *χ*^2^ = 1.610, *P* = 0.205; cardiac death, 0.3% vs. 0.5%, *P* = 0.670; and stent thrombosis, 0.5% vs. 0.4%, *P* \> 0.999). Other prognostic events also occurred at similar rates between the two groups, including MI, revascularization, stroke (both ischemic and hemorrhagic), and all-cause death (all *P* \> 0.05).

###### 

Patient's 2-year follow-up data before and after PSM

  Characteristics         Before PSM   Statistics   *P*       After PSM    Statistics   *P*                    
  ----------------------- ------------ ------------ --------- ------------ ------------ ---------- ----------- ------------
  MACE                    19 (5.2)     166 (4.5)    0.371\*   0.542        19 (5.2)     31 (4.3)   0.514\*     0.474
  MI                      6 (1.6)      65 (1.8)     0.028\*   0.867        6 (1.6)      12 (1.6)   \<0.001\*   \>0.999
   TV-MI                  3 (0.8)      26 (0.7)     --        0.261^†^     3 (0.8)      3 (0.4)    --          0.407^†^
  Revascularization       34 (9.3)     262 (7.1)    2.375\*   0.123        34 (9.3)     49 (6.7)   2.354\*     0.125
   TVR                    18 (4.9)     134 (3.6)    1.537\*   0.215        18 (4.9)     27 (3.7)   0.939\*     0.333
   TLR                    14 (3.8)     89 (2.4)     2.697\*   0.101        14 (3.8)     18 (2.5)   1.610\*     0.205
  Stroke                  5 (1.4)      49 (1.3)     --        0.814^†^     5 (1.4)      8 (1.1)    --          0.769^†^
   Ischemic stroke        3 (0.8)      42 (1.1)     --        0.794^†^     3 (0.8)      7 (1.0)    --          \>0.999^†^
   Hemorrhagic stroke     2 (0.5)      7 (0.2)      --        0.192^†^     2 (0.5)      1 (0.1)    --          0.259^†^
  All-cause death         6 (1.6)      44 (1.2)     --        0.452^†^     6 (1.6)      6 (0.8)    --          0.230^†^
   Cardiac death          1 (0.3)      30 (0.8)     --        0.521^†^     1 (0.3)      4 (0.5)    --          0.670^†^
  Stent thrombosis        2 (0.5)      36 (1.0)     --        0.575^†^     2 (0.5)      3 (0.4)    --          \>0.999^†^
   Acute thrombosis       0 (0.0)      9 (0.2)      --        \>0.999^†^   0 (0.0)      0 (0.0)    --          --
   Subacute thrombosis    0 (0.0)      1 (0.0)      --        \>0.999^†^   0 (0.0)      0 (0.0)    --          --
   Late thrombosis        1 (0.3)      7 (0.2)      --        0.531^†^     1 (0.3)      1 (0.1)    --          \>0.999^†^
   Very late thrombosis   1 (0.3)      19 (0.5)     --        \>0.999^†^   1 (0.3)      2 (0.3)    --          \>0.999^†^

Data were presented as *n* (%) for categorical variables, and median (P~25~, P~75~) for continuous variables. \**χ*^2^ value; ^†^Fisher's exact *P* value. \"-\": Not available. G1-DES: First-generation drug-eluting stent; G2-DES: Second-generation drug-eluting stent; MACEs: Major adverse cardiac events; MI: Myocardial infarction; PSM: Propensity score matching; TLR: Target lesion revascularization; TV-MI: Target vessel-related MI; TVR: Target vessel revascularization.

Based on Kaplan-Meier analysis, the event-free survival rates for both efficacy and safety endpoints were not statistically different between the G1-DES and G2-DES groups after PSM (MACE, *P* = 0.455; TV-MI, *P* = 0.386; TVR, *P* = 0.304; TLR, *P* = 0.189; cardiac death, *P* = 0.530; and stent thrombosis, *P* = 0.748; [Figure 1](#F1){ref-type="fig"}). Multivariate Cox proportional hazard regression analysis demonstrated that the stent type was not an independent predictive factor for all endpoint events regardless of PSM (all *P* \> 0.05; [Figure 2](#F2){ref-type="fig"}).

![Kaplan-Meier analysis for endpoint event-free survivals after PSM (G1-DES, *n* = 364; G2-DES, *n* = 728). Kaplan-Meier analysis of 2-year event-free survival data for (a) MACE, (b) TV-MI, (c) TVR, (d) TLR, (e) cardiac death, and (f) stent thrombosis. G1-DES: First-generation drug-eluting stent; G2-DES: Second-generation drug-eluting stent; MACEs: Major adverse cardiac events; MI: Myocardial infarction; TLR: Target lesion revascularization; TV-MI: Target vessel-related myocardial infarction; TVR: Target vessel revascularization; PSM: Propensity score matching.](CMJ-131-1397-g001){#F1}

![Multivariate Cox proportional regression analysis for efficacy, safety, and other prognostic endpoints. *HRs* before (a) and after PSM (b). \*Adjusted for hospital stay, staged PCI, previous CABG, hypertension, number of TVs, LAD/LCX/RCA involvement, *de novo*/B~2~/C type/CTO lesion, stent overlapping, IABP application, average stent length, and use of β-blockers and DAPT for 2 years. CABG: Coronary artery bypass grafting; *CI*: Confidence interval; CTO: Chronic total occlusion; DAPT: Dual antiplatelet therapy; G1-DES: First-generation drug-eluting stent; G2-DES: Second-generation drug-eluting stent; *HRs*: Hazard ratios; IABP: Intra-aortic balloon pumping; LAD: Left anterior descending artery; LCX: Left circumflex artery; MACEs: Major adverse cardiac events; MI: Myocardial infarction; PCI: Percutaneous coronary intervention; PSM: Propensity score matching; RCA: Right coronary artery; TLR: Target lesion revascularization; TV: Target vessel; TV-MI: Target vessel-related myocardial infarction; TVR: Target vessel revascularization.](CMJ-131-1397-g002){#F2}

D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

This prospective observational study from a high-volume PCI center revealed the following: (1) the incidences of efficacy and safety endpoint events were similar between G1-DES and G2-DES, including MACE, TV-MI, TVR, TLR, cardiac death, and stent thrombosis, and (2) the stent type was not predictive of these prognostic events.

Compared with G1-DESs, G2-DESs are characterized by novel stent platforms, more lipophilic sirolimus analogues, and/or more biocompatible polymers. These advantages enabled a tremendous decrease in adverse events after PCI including reduced stent thrombosis and restenosis.\[[@ref14][@ref15]\] However, evidence supports similar outcomes between G1-DES and G2-DES. In the SORT OUT IV Trial, a large-scale prospective randomized study comparing the performance of a first-generation sirolimus-eluting stent (Cypher Select Plus, Cordis) and second-generation everolimus-eluting stents (Promus, Boston Scientific and Xience V, Abbott Vascular), incidences and risks of TV-MI, TVR, TLR, and cardiac death were similar between the two groups at the 3-year follow-up.\[[@ref16]\] The SORT OUT IV trial also found that definite, probable, or possible stent thrombosis was not significantly different between the two groups at 3 years, despite the finding that patients were predisposed to definite- and very late-stent thrombosis following G1-DES implantation. Our previous study also found that G1-DES had similar efficacy and safety profiles to G2-DES in patients with stable coronary artery disease.\[[@ref11]\]

Despite these findings, controversy remains regarding whether G2-DESs outperform G1-DES in patients with ACS, and evidence is lacking, especially in certain ethnic groups. Patients with ACS have higher risks of adverse cardiac events after PCI;\[[@ref12][@ref17]\] consequently, careful selection of the PCI strategy, including stent type, is necessary to improve therapeutic benefits. In the current study, we found no significant differences regarding MACE and its components, as well as stent thrombosis at the 2-year follow-up, similar to the findings in a substudy of the SORT OUT IV.\[[@ref18]\] In the substudy, second-generation everolimus-eluting stents were demonstrated to have similar incidences and risks of MI, TLR, cardiac death, and stent thrombosis compared with first-generation sirolimus-eluting stents at the 18-month follow-up. Furthermore, a SORT OUT III substudy including 1052 patients with ACS revealed that a first-generation sirolimus-eluting stent (Cypher Select and Cypher Select Plus, Cordis) had similar incidences and risks of MI, cardiac death, and definite stent thrombosis compared with second-generation zotarolimus-eluting stents (Endeavor, Medtronic), despite the finding that the second-generation zotarolimus-eluting stent had higher associated risks of MACE and TVR.\[[@ref8]\] Compared with these trials, the study pooled the data for stent type, enabling comparisons between not only G1- and G2-DES but also different stents within the same generation.

For various reasons, including economic concerns and medical insurance, G1-DESs are still being used in some countries, especially in local hospitals. The present study added evidence to their efficacy and safety for clinical application in patients with ACS. Although MACE had a higher incidence in the G1-DES group compared with the G2-DES group (before PSM: 5.2% vs. 4.5%, respectively, *χ*^2^ = 0.371, *P* = 0.542; after PSM: 5.2% vs. 4.3%, respectively, *χ*^2^ = 0.514, *P* = 0.474), the difference was not statistically significant, and the stent type was not predictive of MACE and its individual components. Similarly, the incidence and the risk of stent thrombosis were not significantly different between G1-DES and G2-DES. In a pathological study including 204 human autopsy lesion samples, the frequency of neoatherosclerosis was similar among second-generation everolimus-eluting stents (Promus, Boston Scientific and Xience V, Abbott Vascular), a first-generation sirolimus-eluting stent (Cypher, Cordis), and a first-generation paclitaxel-eluting stent (Taxus Express or Taxus Liberté, Boston Scientific).\[[@ref19]\] This finding might in part explain the study finding that the efficacy endpoints were similar between G1-DES and G2-DES. The pathological study also revealed that definite-late or very-late stent thrombosis rates were lower for G2-DES compared with G1-DES, agreeing with the widespread idea that G2-DES reduces the risk of stent thrombosis.\[[@ref20]\] In contrast, this study included definite, probable, and possible stent thrombosis data during follow-up, and we found that cumulative thrombosis was not different between G1-DES and G2-DES (respectively: before PSM: 0.5% vs. 1.0%, Fisher\'s exact *P* = 0.575; after PSM: 0.5% vs. 0.4%, Fisher\'s exact *P* \> 0.999). The overall stent thrombosis rate was actually low in our 2-year follow-up study, and the relatively small sample size and short follow-up might mean that the study was underpowered to detect statistical differences in stent thrombosis between G1-DES and G2-DES. In this study, ACS was primarily related to unstable angina (66.51%), which has a lower risk of stent thrombosis compared with STEMI and NSTEMI.\[[@ref21]\] Furthermore, up to 95.4% of patients received dual antiplatelet therapy for 1 year, and 28.7% patients were still receiving dual antiplatelet therapy at the 2-year follow-up, which might also have played an important role in preventing stent thrombosis in our patients.

Despite the encouraging findings, this study has several limitations. First, as in any nonrandomized study, the study is limited by the imbalance of patient and procedure selection between the two groups; however, we performed PSM to minimize dissymmetry between the groups. Second, the relatively small sample size of our single-center study hampered the power of the study, and the follow-up period may be insufficient to illuminate long-term outcomes after PCI compared with existing studies assessing 5-year follow-up data. Because of these longer studies, we are performing longer follow-up in our study patients. Third, G1-DES use will eventually decrease in our country; however, currently in most cases, G1-DES selection is associated with higher insurance compensation. It is difficult to say whether factors other than stent type affect outcomes in patients receiving G1-DES, for example, adequate use of necessary medications including statins and regular examinations after PCI. We are considering these factors in our future work.

In conclusion, in this prospective observational study in patients with ACS, we find that G1-DES have similar efficacy and safety compared with G2-DES at the 2-year follow-up. Stent type is not an independent risk factor for adverse outcomes, including stent thrombosis.
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